Clinical Summaries and Commentaries™: Updates from Atlanta – Therapeutic Advancements in Rheumatoid Arthritis

Released On
Februrary 28, 2020

Expires On
Februrary 28, 2021

Media Type

Completion Time
90 minutes

Allergy & Immunology, Dermatology, Hospitalist, Pathology, Primary Care, Rheumatology

Rheumatoid Arthritis

Scroll to the Bottom of this Information to Begin this Course

This activity is provided by Physicians' Education Resource®, LLC .

Supported by educational grants from AbbVie Inc and Sanofi Genzyme and Regeneron Pharmaceuticals.

Credit Available

  • Physicians — maximum of 1.5 AMA PRA Category 1 Credit(s)

All other health care professionals completing this course will be issued a statement of participation.

Target Audience

This educational activity is directed toward rheumatologists, specialty nurse practitioners, specialty physician assistants, family physicians/primary care physicians, and additional healthcare providers involved in the treatment and management of RA.

Program Overview

This online activity is designed to update clinicians on data presented at the 2019 American College of Rheumatology/Association of Rheumatology Professionals (ACR/ARP) Annual Meeting, held November 8 to 13 in Atlanta, Georgia. This Clinical Summaries and Commentaries™ continuing medical education (CME) activity facilitates critical assessment and clinical integration of new evidence, when appropriate. The activity reviews 8 abstracts from the meeting, with a focus on rheumatoid arthritis (RA). For each abstract, a text summary of key clinical data is accompanied by perspectives from expert thought leaders, who provide insights into how clinicians can apply these findings to their clinical practice to improve patient care.

Learning Objectives

Upon completion of this educational activity, you should be better prepared to:

  • Interpret the potential impact on clinical practice of recent discussion from major conferences and meetings
  • Outline emerging data for currently approved as well as investigational therapy and discuss their clinical implications in the management of patients with RA
  • Utilize evidence-based care to improve and personalize management of patients with RA, including management of comorbid conditions


Jon T Giles, MD, MPH

Associate Professor of Medicine
Department of Medicine/Division of Rheumatology
Columbia University, Vagelos School of Physicians & Surgeons
New York, NY

Jonathan Kay, MD

Professor of Medicine and Population and Quantitative Health Sciences
Timothy S. and Elaine L. Peterson Chair in Rheumatology
University of Massachusetts Medical School
Worcester, MA
Attending Physician
Division of Rheumatology
UMass Memorial Medical Center
Worchester, MA

Accreditation Statement

Physicians’ Education Resource®, LLC, is a accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Physicians’ Education Resource®, LLC designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit™.Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosures of Conflicts of Interest

Jon T. Giles, MD, MPH

  • Grant/Research Support: Pfizer
  • Consultant: Lilly, AbbVie, Bristol-Myers Squibb, UBS.

Jonathan Kay, MD

  • Grant/Research Support: (paid to the University of Massachusetts Medical School): Gilead Sciences, Inc; Pfizer Inc; UCB, Inc;
  • Consultant: Alvotech Suisse AG; Arena Pharmaceuticals, Inc; Boehringer Ingelheim GmbH; Celltrion Healthcare Co., Ltd; Merck Sharp & Dohme Corp; Mylan Inc; Novartis AG; Samsung Bioepis; Sandoz Inc; UCB, Inc.

The staff of Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.

Instructions for Participation and Credit

  • You will need to log in to participate in the activity.
  • Each presentation may contain an interactive question(s). You may move forward through the presentation; however, you may not go back to change answers or review audio files/content until you finish the presentation.
  • At the end of the activity, “Educational Content” will be available for your reference.
  • In order to receive a CME Certificate, you must complete the activity.
  • Complete the Posttest and the Evaluation, and then click on “Request for Credit.” You may immediately download a CME Certificate upon completion of these steps.

Hardware and Software Requirements

This site is best viewed with an HTML5 compatible browser. You can visit the independent (3rd party) site to determine if you have the latest version of your browser.

Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, and Real Networks Real One Player.

Discloseure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent clinical judgment of a physician relative to diagnostic or treatment options for a specific patient’s medical condition.

The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or the company that provided commercial support.

Disclosure Policy and Resolution of Conflicts of Interest (COI)

As a sponsor accredited by the ACCME, it is the policy of PER® to ensure fair balance, independence, objectivity, and scientific rigor in all of its CME activities. In compliance with ACCME guidelines, PER® requires everyone who is in a position to control the content of a CME activity to disclose all relevant financial relationships with commercial interests. The ACCME defines “relevant financial relationships” as financial relationships in any amount occurring within the past 12 months that creates a COI.

Additionally, PER® is required by ACCME to resolve all COI. PER® has identified and resolved all COI prior to the start of this activity by using a multistep process.